Main caricature of Dekel Gelbman, who is speaking at HLTH and is CEO at FDNA Overlay caricature of Dekel Gelbman, who is speaking at HLTH and is CEO at FDNA

Dekel Gelbman



As the founding CEO of FDNA, Dekel Gelbman leads the corporate and business strategy of a digital health company that develops artificial intelligence technologies and SaaS platforms used by thousands of clinical, research, and lab sites globally in the clinical genomics space. FDNA has created a new gold-standard—next-generation phenotyping (NGP)—technologies that capture, structure, and analyze complex human physiological data to produce actionable genomic insights from next-generation sequencing data. Since it’s founding, FDNA has positioned itself at the forefront of AI, genomics, and personalized medicine.

Prior to joining FDNA, Mr. Gelbman was a practicing corporate and transactional attorney working for leading law firms, including among others, Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates. Mr. Gelbman’s experience includes working closely with a variety of technology and biotech companies, at all stages, from startups through growth stage companies, and to mature, publicly-traded companies. He holds an LL.B and an MBA in finance.

See All Speakers

Some additional speakers you may like

VP, Healthcare
Lyft Business
CEO & Founder
Virta Health
President and CEO
VP, Healthcare Solutions
AT&T Business